Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – As populations age and chronic illnesses become more widespread, healthcare systems around the world are being pushed to their limits. But a new wave of solutions is emerging, with artificial intelligence showing promise across diagnostics, drug development, and clinical operations. From easing clinician workloads with voice-enabled tools to deploying AI agents that streamline decision-making, the benefits are already being felt. Driving this progress are a number of forward-looking companies making real advancements in the space, including Avant Technologies, Inc. (OTCQB: AVAI), Claritev Corporation (NYSE: CTEV), iRhythm Technologies, Inc. (NASDAQ: IRTC), Caris Life Sciences, Inc. (NASDAQ: CAI), and Healthcare Triangle Inc. (NASDAQ: HCTI).
Private equity investors say 2025 could outpace 2024 as one of the biggest years yet for AI-powered health tech. Recent private raises include $101 million for Tennr, $45 million for Ellipsis Health, and $28 million for Autonomize AI. Meanwhile, in the public markets, several companies are moving beyond hype with real-world AI deployments already underway.
Avant Technologies, Inc. (OTCQB: AVAI) just signaled its biggest move yet: the creation of a new company dedicated to developing a potential treatment for diabetes. According to their latest update, Avant is set to launch either a joint venture, partnership, or an acquisition to accomplish this intention as it expands its interests in diabetes, which impacts over 500 million people globally.
Avant’s flagship Vision AI tech is designed to detect the early markers of diseases like diabetic retinopathy, which is the leading cause of blindness among working age adults. Vision AI is a cutting-edge, AI-driven platform that can detect diabetic retinopathy and other retinal diseases with high accuracy and speed using retinal scans, as well as diseases unrelated to the retina like cardiovascular disease, prediabetes and type 2 diabetes, fatty liver diseases, and chronic kidney disease.
“It is the work we’re doing with Ainnova to screen diabetes patients to identify the early signs of diabetic retinopathy that is driving Avant to contribute even more to the fast-growing disease—a potential treatment,” said Chris Winter, CEO of Avant Technologies. “We are exploring several promising opportunities to get involved in the development of a treatment for diabetes globally, and if successful, we want to be ready to hit the ground running with the formation of a company to house that opportunity.”
Over 30% of those living with diabetes will develop diabetic retinopathy, a disease that can be prevented with an accurate diagnosis. More recently, Avant and joint-venture partner Ainnova Tech have begun offering free Vision AI scans inside Grupo Dökka’s Fischel and La Bomba pharmacy chains.
"As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment, connecting every step of the journey," said Vinicio Vargas, CEO of Ainnova Tech and board member of Ai-nova Acquisition Corp. "We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive, the well-being of the diabetic patient."
Back in late 2024, Avant entered into the joint venture with Ainnova Tech to form Ai-nova Acquisition Corp (AAC) to advance and commercialize Ainnova’s technology portfolio, including the Vision AI platform, and its versatile retinal cameras. Avant now expects that a new relationship will allow it to expand its diabetes program to both identify the early markers of the disease and to treat diabetes.
Recently, Avant signed a non-binding letter of intent to acquire 100% of Ainnova Tech—bringing leadership, data, and intellectual property together ahead of a scheduled FDA pre-submission meeting in July. Folding the joint venture into a single public entity would remove the current holding-company structure, streamlining everything from regulatory filings to revenue recognition. Management sees the unified cap table as a potential draw for both investors and strategic partners.
While the legal teams work through due diligence, engineers are finalizing a low-cost, automated retinal camera built to work seamlessly with the Vision AI platform. Legacy fundus cameras can run into the tens of thousands and typically require skilled operators. Avant’s prototype is fully automated, cloud-connected, and designed for a fraction of the cost. If performance holds up to internal testing, the system could enable large-scale diabetic screenings in clinics and low-resource settings—without the need for additional specialist staff.
Vision AI is also expanding beyond diabetic eye disease. A patented dementia-risk module—pairing a five-minute blood test with AI pattern recognition—is now in validation, while cardiovascular-risk analytics are advancing through pilot studies across Latin America. Because every new use case plugs into the same software backbone, Avant looks more like a scalable platform than a single-product company.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Claritev Corporation (NYSE: CTEV) has officially joined the Coalition for Health AI (CHAI), a collaborative effort aimed at building responsible frameworks for safe and fair AI in healthcare. The company brings decades of experience in healthcare claims data and AI-powered cost optimization, serving over 700 payors and 60 million consumers.
"Joining CHAI is a natural extension of our mission to improve healthcare affordability and transparency through responsible, data-driven innovation," said Fernando Schwartz, Chief Artificial Intelligence Officer at Claritev. "We're proud to align with a coalition that shares our values and is actively shaping the future of health AI."
As a CHAI member, Claritev will participate in key working groups focused on privacy, fairness, and utility. This move strengthens its position as a stakeholder in the future of regulated, transparent health tech.
iRhythm Technologies, Inc. (NASDAQ: IRTC) unveiled new real-world evidence at the American Diabetes Association’s 2025 conference, identifying a strong link between atrial fibrillation (AF) and adverse outcomes in patients with both type 2 diabetes and chronic kidney disease. The study, which analyzed data from over 2.4 million patients, found that AF was tied to significantly higher risks of heart failure, stroke, and death.
“These findings support a growing body of evidence that heart rhythm disorders are not just late-stage complications—they often emerge much earlier, silently, and in ways that may help us better identify patients at rising risk,” said Mintu Turakhia, MD, iRhythm’s Chief Medical Officer, Chief Scientific Officer, and EVP of Product Innovation. “For patients living with diabetes and kidney disease, earlier detection of these arrhythmias may offer a window to take action before more serious events occur.”
These findings reinforce the importance of early detection and monitoring of cardiac arrhythmias in high-risk populations. The research adds to growing calls for integrating proactive cardiac screening into diabetes care pathways.
Caris Life Sciences, Inc. (NASDAQ: CAI) recently launched its IPO on June 18, 2025, raising nearly $500 million with a $21/share offering that exceeded its expected range. The Texas-based company applies next-generation sequencing and machine learning to build a multimodal clinico-genomic database aimed at advancing cancer diagnostics and therapeutics.
Despite recent sector volatility, Caris’s IPO was well-received, signaling investor confidence in its AI-powered precision medicine platform. The company plans to use proceeds to expand its commercial reach and further develop its suite of oncology testing solutions.
Healthcare Triangle Inc. (NASDAQ: HCTI) has launched QuantumNexis, a new subsidiary focused on delivering generative AI-driven SaaS solutions for the global healthcare market. Announced at a private event in Malaysia, QuantumNexis will serve as the company’s innovation engine for digital health modernization and recurring revenue.
"QuantumNexis is a giant leap forward in AI-driven healthcare, because it leverages advanced machine learning capabilities, and predictive analytics,” said Sujatha Ramesh, COO of HCTI. “QuantumNexis empowers healthcare providers with actionable insights that enable faster diagnoses, improves patient outcomes, and delivers operational efficiency.”
The new brand’s debut products include Ziloy, a personalized mental wellness tool, and Ezovion, a hospital information management system aimed at transforming workflows. This launch marks a strategic expansion of HCTI’s presence into high-growth Southeast Asian markets.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
Baystreet.ca
cs@baystreet.ca
(250) 999-4849
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
